BRIEF—Real-world data show benefits of long-acting antipsychotics

Janssen has released data from a real world evidence study supporting the benefits of long-acting antipsychotics (LATs) in reducing the risk of mortality among patients with schizophrenia.

The  study of a cohort of almost 30,000 people in Sweden found that LATs are associated with a 33% lower risk of mortality than corresponding oral antipsychotics.

Published in Schizophrenia Research, the study shows the lowest mortality was observed for Risperdal (risperidone), Abilify (aripiprazole) and Invega (paliperidone).

The study also showed that LATs result in a 22% risk reduction of re-hospitalisation compared to corresponding oral antipsychotics.

Therapy area head Mikael Själin said: "This evidence demonstrates that antipsychotics, and particularly LATs can help to keep patients out of hospital, ultimately giving people living with schizophrenia greater independence and an opportunity to focus on their future."